Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: A pilot open‐label study
Identifieur interne : 002442 ( Main/Exploration ); précédent : 002441; suivant : 002443Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: A pilot open‐label study
Auteurs : Laura Marsh [États-Unis] ; Kevin Biglan [États-Unis] ; Melissa Gerstenhaber [États-Unis] ; James R. Williams [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2009-01-30.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- Adrenergic Uptake Inhibitors (administration & dosage), Adrenergic Uptake Inhibitors (adverse effects), Adrenergic Uptake Inhibitors (therapeutic use), Adult, Aged, Antiparkinson Agents (administration & dosage), Antiparkinson Agents (therapeutic use), Atomoxetine, Bipolar Disorder (chemically induced), Cognition, Cognition Disorders (drug therapy), Cognition Disorders (etiology), Cognitive disorder, Drug Therapy, Combination, Female, Gastrointestinal Diseases (chemically induced), Humans, Male, Middle Aged, Nervous system diseases, Nootropic Agents (administration & dosage), Nootropic Agents (adverse effects), Nootropic Agents (therapeutic use), Norepinephrine, Parkinson Disease (complications), Parkinson Disease (psychology), Parkinson disease, Parkinson's disease, Pilot Projects, Prefrontal Cortex (drug effects), Prefrontal Cortex (physiopathology), Propylamines (administration & dosage), Propylamines (adverse effects), Propylamines (therapeutic use), Psychological Tests, Psychotropic Drugs (administration & dosage), Psychotropic Drugs (therapeutic use), Severity of Illness Index, Treatment, Treatment Outcome, atomoxetine, cognition, executive dysfunction, norepinephrine reuptake inhibition.
- MESH :
- chemical , administration & dosage : Adrenergic Uptake Inhibitors, Antiparkinson Agents, Nootropic Agents, Propylamines, Psychotropic Drugs.
- chemical , adverse effects : Adrenergic Uptake Inhibitors, Nootropic Agents, Propylamines.
- chemical , therapeutic use : Adrenergic Uptake Inhibitors, Antiparkinson Agents, Nootropic Agents, Propylamines, Psychotropic Drugs.
- chemically induced : Bipolar Disorder, Gastrointestinal Diseases.
- complications : Parkinson Disease.
- drug effects : Prefrontal Cortex.
- drug therapy : Cognition Disorders.
- etiology : Cognition Disorders.
- physiopathology : Prefrontal Cortex.
- psychology : Parkinson Disease.
- Adult, Aged, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Pilot Projects, Psychological Tests, Severity of Illness Index, Treatment Outcome.
Abstract
Executive dysfunction (ED) is a prominent and often disabling feature of cognitive impairment in Parkinson's disease (PD). Few studies have examined treatments. Given the role of noradrenergic pathology in ED, atomoxetine, a norepinephrine reuptake inhibitor indicated for attention deficit hyperactivity disorder (ADHD), may be a potential treatment for PD‐related ED. Twelve patients with PD and disabling ED completed an 8‐week pilot open‐label, flexible dose (25–100 mg/day) trial of atomoxetine. On primary outcome measures, atomoxetine was associated with improved ED based on the Clinical Global Impression‐Change Scale (75% positive response rate; 95% CI: 43–95%, P < 05) and behavioral measures of ED [Frontal Systems Behavior Scale (FrSBE) Executive Dysfunction and Connors Adult ADHD Rating Scale (CAARS) inattention/memory subscales]. Adverse effects included sleep and gastrointestinal disturbances and hypomania. Atomoxetine is tolerable in PD and may benefit clinical manifestations of ED, warranting further study in controlled trials. © 2008 Movement Disorder Society
Url:
- https://api.istex.fr/document/E25F0E4646B06E25E05485ED8802008C9977F318/fulltext/pdf
- http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2683743
DOI: 10.1002/mds.22307
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000D86
- to stream Istex, to step Curation: 000D86
- to stream Istex, to step Checkpoint: 001044
- to stream Pmc, to step Corpus: 000043
- to stream Pmc, to step Curation: 000043
- to stream Pmc, to step Checkpoint: 000420
- to stream PubMed, to step Corpus: 001F22
- to stream PubMed, to step Curation: 001F22
- to stream PubMed, to step Checkpoint: 001F45
- to stream Ncbi, to step Merge: 002442
- to stream Ncbi, to step Curation: 002442
- to stream Ncbi, to step Checkpoint: 002442
- to stream Main, to step Merge: 002D03
- to stream PascalFrancis, to step Corpus: 000F80
- to stream PascalFrancis, to step Curation: 001D39
- to stream PascalFrancis, to step Checkpoint: 000F75
- to stream Main, to step Merge: 003072
- to stream Main, to step Curation: 002442
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: A pilot open‐label study</title><author><name sortKey="Marsh, Laura" sort="Marsh, Laura" uniqKey="Marsh L" first="Laura" last="Marsh">Laura Marsh</name></author><author><name sortKey="Biglan, Kevin" sort="Biglan, Kevin" uniqKey="Biglan K" first="Kevin" last="Biglan">Kevin Biglan</name></author><author><name sortKey="Gerstenhaber, Melissa" sort="Gerstenhaber, Melissa" uniqKey="Gerstenhaber M" first="Melissa" last="Gerstenhaber">Melissa Gerstenhaber</name></author><author><name sortKey="Williams, James R" sort="Williams, James R" uniqKey="Williams J" first="James R." last="Williams">James R. Williams</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:E25F0E4646B06E25E05485ED8802008C9977F318</idno><date when="2009" year="2009">2009</date><idno type="doi">10.1002/mds.22307</idno><idno type="url">https://api.istex.fr/document/E25F0E4646B06E25E05485ED8802008C9977F318/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000D86</idno><idno type="wicri:Area/Istex/Curation">000D86</idno><idno type="wicri:Area/Istex/Checkpoint">001044</idno><idno type="wicri:doubleKey">0885-3185:2009:Marsh L:atomoxetine:for:the</idno><idno type="wicri:source">PMC</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2683743</idno><idno type="RBID">PMC:2683743</idno><idno type="wicri:Area/Pmc/Corpus">000043</idno><idno type="wicri:Area/Pmc/Curation">000043</idno><idno type="wicri:Area/Pmc/Checkpoint">000420</idno><idno type="wicri:source">PubMed</idno><idno type="wicri:Area/PubMed/Corpus">001F22</idno><idno type="wicri:Area/PubMed/Curation">001F22</idno><idno type="wicri:Area/PubMed/Checkpoint">001F45</idno><idno type="wicri:Area/Ncbi/Merge">002442</idno><idno type="wicri:Area/Ncbi/Curation">002442</idno><idno type="wicri:Area/Ncbi/Checkpoint">002442</idno><idno type="wicri:doubleKey">0885-3185:2009:Marsh L:atomoxetine:for:the</idno><idno type="wicri:Area/Main/Merge">002D03</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:09-0104584</idno><idno type="wicri:Area/PascalFrancis/Corpus">000F80</idno><idno type="wicri:Area/PascalFrancis/Curation">001D39</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000F75</idno><idno type="wicri:doubleKey">0885-3185:2009:Marsh L:atomoxetine:for:the</idno><idno type="wicri:Area/Main/Merge">003072</idno><idno type="wicri:Area/Main/Curation">002442</idno><idno type="wicri:Area/Main/Exploration">002442</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: A pilot open‐label study</title><author><name sortKey="Marsh, Laura" sort="Marsh, Laura" uniqKey="Marsh L" first="Laura" last="Marsh">Laura Marsh</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology and Neurological Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Morris K. Udall Parkinson's Disease Research Center of Excellence at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Biglan, Kevin" sort="Biglan, Kevin" uniqKey="Biglan K" first="Kevin" last="Biglan">Kevin Biglan</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology and Neurological Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Current Address: Department of Neurology, University of Rochester Medical School, Rochester, NY</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Gerstenhaber, Melissa" sort="Gerstenhaber, Melissa" uniqKey="Gerstenhaber M" first="Melissa" last="Gerstenhaber">Melissa Gerstenhaber</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Morris K. Udall Parkinson's Disease Research Center of Excellence at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Williams, James R" sort="Williams, James R" uniqKey="Williams J" first="James R." last="Williams">James R. Williams</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Morris K. Udall Parkinson's Disease Research Center of Excellence at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Mental Health, Bloomberg School of Public Health, Johns Hopkins University School of Medicine, Baltimore, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2009-01-30">2009-01-30</date><biblScope unit="vol">24</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="277">277</biblScope><biblScope unit="page" to="282">282</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">E25F0E4646B06E25E05485ED8802008C9977F318</idno><idno type="DOI">10.1002/mds.22307</idno><idno type="ArticleID">MDS22307</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adrenergic Uptake Inhibitors (administration & dosage)</term><term>Adrenergic Uptake Inhibitors (adverse effects)</term><term>Adrenergic Uptake Inhibitors (therapeutic use)</term><term>Adult</term><term>Aged</term><term>Antiparkinson Agents (administration & dosage)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Atomoxetine</term><term>Bipolar Disorder (chemically induced)</term><term>Cognition</term><term>Cognition Disorders (drug therapy)</term><term>Cognition Disorders (etiology)</term><term>Cognitive disorder</term><term>Drug Therapy, Combination</term><term>Female</term><term>Gastrointestinal Diseases (chemically induced)</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Nervous system diseases</term><term>Nootropic Agents (administration & dosage)</term><term>Nootropic Agents (adverse effects)</term><term>Nootropic Agents (therapeutic use)</term><term>Norepinephrine</term><term>Parkinson Disease (complications)</term><term>Parkinson Disease (psychology)</term><term>Parkinson disease</term><term>Parkinson's disease</term><term>Pilot Projects</term><term>Prefrontal Cortex (drug effects)</term><term>Prefrontal Cortex (physiopathology)</term><term>Propylamines (administration & dosage)</term><term>Propylamines (adverse effects)</term><term>Propylamines (therapeutic use)</term><term>Psychological Tests</term><term>Psychotropic Drugs (administration & dosage)</term><term>Psychotropic Drugs (therapeutic use)</term><term>Severity of Illness Index</term><term>Treatment</term><term>Treatment Outcome</term><term>atomoxetine</term><term>cognition</term><term>executive dysfunction</term><term>norepinephrine reuptake inhibition</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Adrenergic Uptake Inhibitors</term><term>Antiparkinson Agents</term><term>Nootropic Agents</term><term>Propylamines</term><term>Psychotropic Drugs</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Adrenergic Uptake Inhibitors</term><term>Nootropic Agents</term><term>Propylamines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Adrenergic Uptake Inhibitors</term><term>Antiparkinson Agents</term><term>Nootropic Agents</term><term>Propylamines</term><term>Psychotropic Drugs</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Bipolar Disorder</term><term>Gastrointestinal Diseases</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Prefrontal Cortex</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Cognition Disorders</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Cognition Disorders</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Prefrontal Cortex</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Drug Therapy, Combination</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Pilot Projects</term><term>Psychological Tests</term><term>Severity of Illness Index</term><term>Treatment Outcome</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Atomoxétine</term><term>Cognition</term><term>Maladie de Parkinson</term><term>Noradrénaline</term><term>Pathologie du système nerveux</term><term>Traitement</term><term>Trouble cognitif</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Executive dysfunction (ED) is a prominent and often disabling feature of cognitive impairment in Parkinson's disease (PD). Few studies have examined treatments. Given the role of noradrenergic pathology in ED, atomoxetine, a norepinephrine reuptake inhibitor indicated for attention deficit hyperactivity disorder (ADHD), may be a potential treatment for PD‐related ED. Twelve patients with PD and disabling ED completed an 8‐week pilot open‐label, flexible dose (25–100 mg/day) trial of atomoxetine. On primary outcome measures, atomoxetine was associated with improved ED based on the Clinical Global Impression‐Change Scale (75% positive response rate; 95% CI: 43–95%, P < 05) and behavioral measures of ED [Frontal Systems Behavior Scale (FrSBE) Executive Dysfunction and Connors Adult ADHD Rating Scale (CAARS) inattention/memory subscales]. Adverse effects included sleep and gastrointestinal disturbances and hypomania. Atomoxetine is tolerable in PD and may benefit clinical manifestations of ED, warranting further study in controlled trials. © 2008 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Maryland</li><li>État de New York</li></region></list><tree><country name="États-Unis"><region name="Maryland"><name sortKey="Marsh, Laura" sort="Marsh, Laura" uniqKey="Marsh L" first="Laura" last="Marsh">Laura Marsh</name></region><name sortKey="Biglan, Kevin" sort="Biglan, Kevin" uniqKey="Biglan K" first="Kevin" last="Biglan">Kevin Biglan</name><name sortKey="Biglan, Kevin" sort="Biglan, Kevin" uniqKey="Biglan K" first="Kevin" last="Biglan">Kevin Biglan</name><name sortKey="Gerstenhaber, Melissa" sort="Gerstenhaber, Melissa" uniqKey="Gerstenhaber M" first="Melissa" last="Gerstenhaber">Melissa Gerstenhaber</name><name sortKey="Gerstenhaber, Melissa" sort="Gerstenhaber, Melissa" uniqKey="Gerstenhaber M" first="Melissa" last="Gerstenhaber">Melissa Gerstenhaber</name><name sortKey="Marsh, Laura" sort="Marsh, Laura" uniqKey="Marsh L" first="Laura" last="Marsh">Laura Marsh</name><name sortKey="Marsh, Laura" sort="Marsh, Laura" uniqKey="Marsh L" first="Laura" last="Marsh">Laura Marsh</name><name sortKey="Williams, James R" sort="Williams, James R" uniqKey="Williams J" first="James R." last="Williams">James R. Williams</name><name sortKey="Williams, James R" sort="Williams, James R" uniqKey="Williams J" first="James R." last="Williams">James R. Williams</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002442 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002442 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:E25F0E4646B06E25E05485ED8802008C9977F318
|texte= Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: A pilot open‐label study
}}
| This area was generated with Dilib version V0.6.23. |  |